The biotech had $4.3 billion in sales at risk.
News & Analysis: Alkermes
A slow launch has investors worried.
ALKS earnings call for the period ending June 30, 2019.
Generic competition is dragging down revenue this year, but it has FDA approvals in the wings.
ALKS earnings call for the period ending March 31, 2019.
Sales of the drugmaker's schizophrenia drug Aristada disappointed investors.
It took a few drugs to get there.
ALKS earnings call for the period ending December 31, 2018.
Earnings per share will more than double for each of these specialty drugmakers.
The company's ALKS-5461 failed to win over the FDA's advisory committee this month.